RRML - Clinical, laboratory and molecular features in essential thrombocythemia

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17

Advanced search

Top 10 downloaded articles
- September 2022 -
Downregulation of hsa-miR-4328... 16
Normality assessment, few para... 12
SPP1 is a biomarker of cervica... 10
Validation of GOD / PAP method... 9
Biomarkers in heart failure: f... 9
The effect of Ulva rigida (C. ... 8
Expressions of TGF-β1 and VEG... 8
COVID-19 associated coagulopat... 7
Approaching Risk Management in... 7
Expression of serum soluble Kl... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 19(2)/2011

Clinical, laboratory and molecular features in essential thrombocythemia

Laura G. Urian, Adrian P. Trifa, Ljubomir Petrov, Mariana Paţiu


Essential thrombocyhtemia is a BCR-ABL negative myeloproliferative disorder (MPD) distinct from polycytemia vera and idiopathic myelofibrosis and characterized by persistent thrombocytosis, excessive proliferation of megakariocytes in the bone marrow, normal erythrocytic mass and the absence of prominent bone marrow fibrosis. In the last few years new information on pathogenesis of myeloproliferative disorders became available: the discovery of an acquired recurrent molecular abnormality in the 14th exon of the JAK2V617F gene resulting in a substitution of valine for phenylalanine at position 617 in the JAK2 protein (V617). We analyzed the recently identified JAK2V617F mutational status, the relevance of mutated allele burden for clinical presentation, thrombosis and hemorrhagic complications.

Keywords: essential thrombocytemia,mutation JAK2 V617F,thrombosis and hemorrhagic complications

  PDF Download full text PDF
(226 KB)
How to cite
Urian LG, Trifa AP, Petrov L, Paţiu M. Clinical, laboratory and molecular features in essential thrombocythemia. Rev Romana Med Lab. 2011;19(2):129-38